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ORIGINAL ARTICLE
Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2
phosphorylation and binding of Smad2 cargo
C Manser1,4, F Guillot1,4, A Vagnoni1, J Davies1, K-F Lau1,2, DM McLoughlin1,3, KJ De Vos1
and CCJ Miller1
1Department of Neuroscience P037, MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London,
Denmark Hill, London, UK; 2Department of Biochemistry, The Chinese University of Hong Kong, Shatin, New Territories,
Hong Kong and 3Department of Psychiatry, Trinity College Institute of Neuroscience, St Patrick’s Hospital, Dublin, Ireland
A recent genome-wide association study identified the
gene encoding lemur tyrosine kinase-2 (LMTK2) as a
susceptibility gene for prostate cancer. The identified
genetic alteration is within intron 9, but the mechanisms
by which LMTK2 may impact upon prostate cancer are
not clear because the functions of LMTK2 are poorly
understood. Here, we show that LMTK2 regulates a
known pathway that controls phosphorylation of kinesin-1
light chain-2 (KLC2) by glycogen synthase kinase-3b
(GSK3b). KLC2 phosphorylation by GSK3b induces the
release of cargo from KLC2. LMTK2 signals via protein
phosphatase-1C (PP1C) to increase inhibitory phosphor-
ylation of GSK3b on serine-9 that reduces KLC2
phosphorylation and promotes binding of the known
KLC2 cargo Smad2. Smad2 signals to the nucleus in
response to transforming growth factor-b (TGFb) recep-
tor stimulation and transport of Smad2 by kinesin-1 is
required for this signalling. We show that small interfering
RNA loss of LMTK2 not only reduces binding of Smad2
to KLC2, but also inhibits TGFb-induced Smad2 signal-
ling. Thus, LMTK2 may regulate the activity of kinesin-1
motor function and Smad2 signalling.
Oncogene (2012) 31, 2773–2782; doi:10.1038/onc.2011.437;
published online 26 September 2011
Keywords: glycogen synthase kinase-3b; protein phos-
phatase-1C; transforming growth factor-b; amyotrophic
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Introduction
Lemur tyrosine kinase-2 (LMTK2) also known as brain-
enriched kinase, apoptosis-associated tyrosine kinase-2,
kinase/phosphatase/inhibitor-2, cyclin-dependent kinase-5
(cdk5)/p35-regulated kinase and KIAA1079 is member of
the lemur family of kinases (Wang and Brautigan, 2002;
Kesavapany et al., 2003; Kawa et al., 2004). These are a
structurally unique group of membrane-associated kinases
comprising LMTK1, LMTK2 and LMTK3. All are
anchored in the membrane by two predicted membrane
spanning regions located at their extreme amino-termini
(a splice isoform of LMTK1 lacks these sequences, but
associates with membranes by palmitoylation) and con-
tain an amino-terminally located kinase domain with a
long carboxy-terminal ‘tail’ (Tomomura et al., 2007). As
such, they have been named after lemurs, the long-tailed
Madagascan primates. Although originally predicted
to be a dual-specificity serine–threonine/tyrosine kinase,
several studies have shown that LMTK2 only targets
serine and threonine residues (Wang and Brautigan, 2002,
2006; Kawa et al., 2004).
Recently, LMTK2 has become the focus of interest
with its identification as a susceptibility gene for
prostate cancer (Eeles et al., 2008; Fitzgerald et al.,
2009; Waters et al., 2009). Somatic mutations in
LMTK2 have also been described in other cancers
(Greenman et al., 2007). The identified genetic alteration
is within intron 9 of the LMTK2 gene, but the
mechanism by which this increases the risk for prostate
cancer is unknown. This is largely because the functions
of LMTK2 are not properly understood. LMTK2
knockout mice are viable, but males are infertile owing
to defects in spermatogenesis involving development of
the acrosome (Kawa et al., 2006). However, LMTK2 is
expressed in most if not all tissues and this suggests that
it has other physiological roles (Wang and Brautigan,
2002; Kesavapany et al., 2003; Kawa et al., 2004;
Tomomura et al., 2007). Indeed, there is evidence that
LMTK2 is involved in endocytic recycling and in
neurons, in nerve growth factor signalling and neurite
outgrowth, although the precise mechanisms by which it
impacts on these processes are unclear (Kawa et al.,
2004; Chibalina et al., 2007; Inoue et al., 2008).
One clue to LMTK2 function comes from the findings
that it interacts with both the cdk5 activator p35 and
protein phosphatase-1C (PP1C) (Wang and Brautigan,
2002; Kesavapany et al., 2003). cdk5/p35 and PP1C
together function in a pathway that regulates intracel-
lular transport of cargoes on kinesin-1 molecular motors
in neurons (Morfini et al., 2004). Kinesin-1 is a
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ubiquitously expressed molecular motor that drives
transport of cargoes along microtubules. Functionally,
most kinesin-1 comprises a heterotetramer of two
kinesin-1 motor proteins (also known as kinesin heavy
chains) and two associated kinesin-1 light chains (KLC):
KLC1 and KLC2 are the two best characterised light-
chain isoforms and are encoded by separate genes
(Rahman et al., 1998; DeBoer et al., 2008; Hirokawa
et al., 2009). Although some cargoes can attach directly
to kinesin-1 motors, many associate with the motor via
KLC1 or KLC2 (Hirokawa et al., 2009). As such, the
mechanisms that mediate binding and release of cargoes
from KLC1/KLC2 represent routes for controlling
kinesin-1-directed intracellular transport; phosphoryla-
tion of KLC1 and KLC2 is one such route (Morfini
et al., 2002, 2004; Vagnoni et al., 2011).
Glycogen synthase kinase-3b (GSK3b) phosphory-
lates KLC2 to cause release of cargo; as such, GSK3b
activity inhibits kinesin-1 transport of at least some
cargoes (Morfini et al., 2002). In addition, a neuronal
signalling pathway to control GSK3b phosphorylation
of KLC2 has been described. This involves cdk5/p35-
mediated inhibitory phosphorylation of PP1C on
threonine-320 (PP1Cthr320), which in turn induces
inhibitory phosphorylation of GSK3b on serine-9
(GSK3bser9). Cdk5/p35 thus inhibits GSK3b phosphor-
ylation of KLC2 and so promotes cargo binding and
transport by kinesin-1 motors (Morfini et al., 2004).
Whether cdk5/p35 directly phosphorylates PP1Cthr320
or whether it induces phosphorylation via some as yet
unidentified kinase is unclear (Morfini et al., 2004;
Li et al., 2007). Whatever the precise mechanism,
phosphorylation of PP1Cthr320 in non-neuronal cells
must involve an alternative kinase as cdk5/p35 activity is
mainly restricted to neurons and muscle (Lew et al.,
1994; Tsai et al., 1994; Fu et al., 2001).
Here, we show that LMTK2 also signals via
PP1Cthr320 and GSK3bser9 phosphorylation to regulate
KLC2 phosphorylation, and that LMTK2 promotes
binding of the known KLC2 cargo Smad2 to KLC2.
Smad2 signals to the nucleus in response to transform-
ing growth factor-b (TGFb) receptor stimulation and
transport of Smad2 by kinesin-1 is required for this
signalling. We also show that small interfering RNA
(siRNA) knockdown of LMTK2 inhibits Smad2 signal-
ling in response to TGFb. As such, our results provide a
novel function for LMTK2 in regulating intracellular
transport.
Results
LMTK2 interacts with PP1C and induces inhibitory
phosphorylation of PP1Cthr320
We screened a human brain yeast two-hybrid library
with the intracellular domain of LMTK2 as described
previously (Chibalina et al., 2007). From this screen, we
obtained a single almost full-length PP1C clone (PP1C
residues 5 to the C terminus). To confirm that LMTK2
interacts with PP1C, we performed immunoprecipita-
tion assays from myc-tagged LMTK2 and PP1C co-
transfected HeLa cells using anti-myc to pull-down
transfected LMTK2. PP1C co-immunoprecipitated with
LMTK2 from LMTK2, but not PP1C-only transfected
cells (Supplementary Figure 1A). In addition, LMTK2
contains a known PP1C binding motif (valine–threo-
nine–phenylalanine; residues 1325–1327 in mouse
LMTK2) and mutation of this site to alanine–threo-
nine–alanine (LMTK2ala1325/1327) reduced the interaction
of LMTK2 with PP1C in the immunoprecipitation
assays (Supplementary Figure 1A).
PP1C activity is negatively regulated by phosphoryla-
tion of threonine320 (Dohadwala et al., 1994). We tested
whether LMTK2 phosphorylates PP1Cthr320 by mon-
itoring phosphorylation of this site using a phospho-
specific PP1Cthr320 antibody in cells co-transfected with
PP1C and either LMTK2, LMTK2ala1325/1327 or control
vector. Transfection of LMTK2 has been shown to
induce increased cellular LMTK2 activity (Kesavapany
et al., 2003). Transfection of LMTK2 but not LMTK2a-
la1325/1327 increased phosphorylation of PP1Cthr320 (Sup-
plementary Figure 1B). The PP1C-binding motif in
LMTK2 (residues 1325–1327) is localised some distance
from the LMTK2 kinase domain (residues 136–406) and
we confirmed that this mutation did not influence
LMTK2 activity by performing in vitro kinase assays
with phosphorylase b as a substrate; phosphorylase b is
a known in vitro LMTK2 substrate (Wang and
Brautigan, 2006). Both LMTK2 and LMTK2ala1325/1327
displayed equivalent activities in these assays (Supple-
mentary Figure 1C). To complement the above studies,
we also monitored how siRNA-induced loss of LMTK2
influenced phosphorylation of PP1Cthr320. Four differ-
ent LMTK2 siRNAs all markedly reduced LMTK2
levels and this led to a corresponding decrease in
PP1Cthr320 phosphorylation (Figure 1a). This effect on
PP1C was not seen in cells treated with two different
control siRNAs or with two different LMTK2 mis-
match siRNAs, none of which influenced LMTK2
expression (Figure 1a).
Thus, LMTK2 interacts with PP1C via sequences
including its consensus PP1C binding motif, and induces
inhibitory phosphorylation of PP1Cthr320. These find-
ings are consistent with previous observations that
identified LMTK2 as a PP1C binding partner via
alternative methods and which likewise demonstrated
that LMTK2 phosphorylates PP1Cthr320 (Wang and
Brautigan, 2002).
LMTK2 inhibits phosphorylation of GSK3bser9
PP1C controls GSK3b activity by modulating phos-
phorylation of GSK3bser9 (Morfini et al., 2004;
Hernandez et al., 2010). Phosphorylation of GSK3bser9
inhibits GSK3b activity (Sutherland et al., 1993;
Stambolic and Woodgett, 1994; Cross et al., 1995).
Moreover, increasing cellular PP1Cthr320 phosphoryla-
tion (which reduces PP1C activity) induces a corre-
sponding increase in GSK3bser9 phosphorylation
(Morfini et al., 2004). As LMTK2 regulates PP1Cthr320
phosphorylation, we therefore enquired whether it might
also regulate GSK3bser9 phosphorylation. To do so, we
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modulated LMTK2 expression in HeLa cells and
monitored PP1Cthr320 phosphorylation by immunoblot-
ting. Transfection of LMTK2 but not LMTK2ala1325/1327
increased GSK3bser9 phosphorylation (Figure 1b). We
also monitored the effect of inhibiting PP1C on LMTK2-
induced phosphorylation. To do so, we treated cells with
tautomycetin, which is a specific inhibitor of PP1 but not
PP2A (Mitsuhashi et al., 2001). Tautomycetin increased
GSK3bser9 phosphorylation in a manner similar to
LMTK2 and transfection of LMTK2 did not increase
further this phosphorylation (Figure 1c). Finally, we
monitored the effect of reducing LMTK2 expression on
GSK3bser9 phosphorylation. Knockdown of LMTK2
expression using four different siRNAs all decreased
GSK3bser9 phosphorylation (Figure 1a). Thus, elevation
and siRNA knockdown of LMTK2 expression induce
complementary changes in phosphorylation of both
PP1Cthr320 and GSK3bser9.
LMTK2 regulation of GSK3bser9 involves PP1C
The above results are consistent with a model whereby
LMTK2 exerts its effect on GSK3bser9 via inhibitory
phosphorylation of PP1Cthr320 and are analogous to
previous studies, which show that cdk5/p35 regulation
of GSK3bser9 phosphorylation also involves PP1Cthr320
phosphorylation in neurons (Morfini et al., 2004).
Indeed, the lack of effect of LMTK2ala1325/1327 (which is
active but does not bind PP1C; Supplementary Figure 1)
on GSK3bser9 phosphorylation provides strong evi-
dence for an involvement of PP1C in this process.
However, to further eliminate the possibility that
LMTK2 directly phosphorylates GSK3bser9, we con-
ducted in vitro phosphorylation studies with LMTK2
and recombinant GSK3b. LMTK2 was isolated by
immunoprecipitation from LMTK2-transfected cells
and equal proportions of the immunoprecipitated kinase
then incubated with recombinant GSK3b or phosphor-
ylase b substrates. In these experiments, LMTK2
phosphorylated phosphorylase b (a known LMTK2
substrate; Wang and Brautigan, 2006), but not GSK3b
(Figures 2a and b). In addition, we monitored
GSK3bser9 phosphorylation in LMTK2 siRNA-treated
cells that were also treated with the PP1 inhibitor
tautomycetin. If LMTK2 regulates GSK3b activity via
an effect on PP1C, then the reduced phosphorylation of
GSK3bser9 seen in LMTK2 siRNA-treated cells should
be abolished in cells also treated with tautomycetin. This
proved to be the case. Thus, tautomycetin increased
GSK3bser9 phosphorylation, but siRNA knockdown of
LMTK2 in these cells had no effect on this increase. By
contrast, in the absence of tautomycetin, LMTK2
knockdown decreased GSK3bser9 phosphorylation
(Figure 2c). As a control for this experiment, we
monitored phosphorylation of c-jun N-terminal kinase
(JNK) in the different samples. Phosphorylation of JNK
is also regulated by PP1 (Mitsuhashi et al., 2003), but
there is no evidence to link this phosphorylation with
LMTK2. Treatment with tautomycetin increased JNK
phosphorylation as described previously (Mitsuhashi
et al., 2003), but siRNA knockdown of LMTK2 had no
effect on this phosphorylation (Figure 2c). Thus, the
effect of LMTK2 on GSK3bser9 phosphorylation
involves PP1C.
LMTK2 induces dephosphorylation of KLC2 and
promotes binding of Smad2, a known KLC2 cargo
GSK3b phosphorylation of KLC2 is regulated by a
pathway involving phosphorylation of PP1Cthr320 and
GSK3bser9 (Morfini et al., 2004). We therefore enquired
whether LMTK2 might signal to regulate KLC2
phosphorylation. To do so, we first modulated LMTK2
expression in cells and monitored phosphorylation of
transfected FLAG-tagged KLC2. As the full comple-
ment of KLC2 sites phosphorylated by GSK3b in vivo
are not known and as there are no phospho-specific
antibodies that detect KLC2 phosphorylated on these
sites, we monitored phosphorylation by use of Pro-Q
Diamond staining of gels (Martin et al., 2003) following
isolation of KLC2 by immunoprecipitation using
Figure 1 siRNA knockdown of LMTK2 decreases PP1Cthr320 and
GSK3bser9 phosphorylation and transfection of LMTK2, but not
LMTK2ala1325/1327, increases GSK3bser9 phosphorylation in HeLa
cells. (a) Cells were mock transfected (no siRNA), or transfected
with two different control siRNAs, two different LMTK2
mismatch siRNAs or four different LMTK2 siRNAs as indicated.
Samples were then probed on immunoblots for total PP1C (PP1C)
and phospho-PP1Cthr320 (PP1C-thr320p), total GSK3b (GSK3b)
and phospho-GSK3bser9 (GSK3b-ser9p), and LMTK2 as indi-
cated. (b) Cellular phosphorylation of GSK3bser9 by LMTK2.
Cells were co-transfected with GSK3b and either control vector
(Ctrl), LMTK2 or LMTK2ala1325/1327 (LMTK2ala). Samples were
probed on immunoblots for total GSK3b (GSK3b), phosphory-
lated GSK3bser9 (GSK3b-ser9p) and LMTK2 using the myc tag.
LMTK2 but not LMTK2ala1325/1327 increased phosphorylation of
GSK3bser9. (c) Tautomycetin increases phosphorylation of
GSK3bser9 and does not affect LMTK2-induced phosphorylation
of GSK3bser9. Cells were co-transfected with GSK3b and either
control vector (Ctrl) or LMTK2, treated with (þ ) or without ()
tautomycetin (TMC) as indicated and analysed on immunoblots
for total GSK3b (GSK3b), phosphorylated GSK3bser9 (GSK3b-
ser9p) and LMTK2 using the myc tag.
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anti-FLAG antibody. Pro-Q Diamond has now been
used in numerous studies to monitor changes in protein
phosphorylation (for example, Rahman-Roblick et al.,
2008).
Co-transfection of FLAG-KLC2 with LMTK2 but
not LMTK2ala1325/1327 decreased KLC2 phosphorylation
(Figure 3a). By contrast, siRNA knockdown of LMTK2
led to an increase in KLC2 phosphorylation (Figure 3b).
Moreover, this increase in KLC2 phosphorylation seen
in LMTK2 siRNA-treated cells was abolished in cells
also treated with tautomycetin (Figure 3b). The lack of
effect of LMTK2ala1325/1327 on KLC2 phosphorylation
and the abrogation of the LMTK2 siRNA effect on
KLC2 phosphorylation with tautomycetin together
provide strong support for the notion that the inhibitory
effect of LMTK2 on KLC2 phosphorylation involves
PP1C.
As phosphorylation of KLC2 is a mechanism for
controlling its interaction with cargoes (Morfini et al.,
2002), we investigated how LMTK2 influenced binding
of KLC2 to Smad2. Smad2 is a known kinesin-1 cargo
and KLC2 binding partner (Batut et al., 2007). Smad2
co-immunoprecipitated with FLAG-KLC2 from co-
transfected cells, which is in agreement with previous
studies (Batut et al., 2007; Figure 4a). However, co-
transfection of LMTK2 to elevate expression led to an
increase in the amount of Smad2 that co-immunopre-
cipitated with KLC2 (Figure 4a). By contrast, siRNA
knockdown of LMTK2 reduced the amount of Smad2
bound to KLC2 in these immunoprecipitation assays
and this effect was abrogated in cells also treated with
inhibitor VIII, a specific GSK3b inhibitor (Bhat et al.,
2003; Figure 4b). Thus, LMTK2 negatively regulates
KLC2 phosphorylation and promotes its binding to
Smad2, a known KLC2 cargo.
siRNA knockdown of LMTK2 inhibits TGFb-induced
Smad2 signalling
Smad2 signals to the nucleus following TGFb receptor
stimulation. In response to TGFb, Smad2 is phosphory-
Figure 2 LMTK2 regulation of GSK3bser9 phosphorylation
involves PP1C. (a, b) In vitro phosphorylation ([g-32P] incorpora-
tion) of phosphorylase b, but not GSK3b by LMTK2. LMTK2
was isolated by immunoprecipitation from LMTK2-transfected
cells using the myc tag. Equal proportions of immunoprecipitated
LMTK2 were then incubated with phosphorylase b (a) or GSK3b
(b) substrates in reactions containing [g-32P]ATP. () and (þ ) refer
to the absence or presence of myc antibody in the immunopreci-
pitations to isolate active kinase. Reactions were also performed
with no substrate as indicated. The upper panels show the
autoradiographs; the lower panels are the corresponding Coomas-
sie-stained gels to show equal amounts of substrates in the reaction
mixes. Phosphorylase b and GSK3b are indicated on the
Coomassie gels; Ig indicates immunoglobulin heavy chain of the
immunoprecipitating antibody. Also shown (bottom panels) are
immunoblots with anti-myc to demonstrate equal amounts of
LMTK2 in the reaction mixes. All autorads were exposed for the
same time. (c) Reduced GSK3bser9 phosphorylation in LMTK2
siRNA-transfected HeLa cells in the absence, but not in the
presence of the PP1C inhibitor tautomycetin. Cells were transfected
with control or LMTK2 siRNAs and treated with tautomycetin as
indicated. Samples were probed on immunoblots for total GSK3b
(GSK3b) and phospho-GSK3bser9 (GSK3b-ser9p) as shown. The
stronger labelling for phospho-GSK3bser9 in the presence of
tautomycetin is consistent with a role for PP1C in regulating
phosphorylation of this site and is in agreement with previous
studies (Morfini et al., 2004). Also shown are control blots for total
JNK (p46 and p54 isoforms) (JNK), phosphorylated JNK (JNK-p)
and LMTK2 to confirm knockdown. Tautomycetin increases
phosphorylation of JNK, but siRNA knockdown of LMTK2 has
no effect on JNK phosphorylation.
Figure 3 LMTK2 induces dephosphorylation of KLC2. (a) Pro-Q
Diamond (Pro-Q) phospho-staining of KLC2 isolated from HeLa
cells co-transfected with KLC2 and either control vector (Ctrl),
LMTK2 or LMTK2ala1325/1327 (LMTK2ala). Transfected KLC2
was isolated by immunoprecipitation using the FLAG tag and then
analysed by Pro-Q Diamond phospho-staining after SDS–PAGE.
Also shown are immunoblots of immunoprecipitated KLC2 (to
demonstrate equal amounts of KLC2 in the different samples) and
transfected LMTK2, which was detected using the myc tag.
LMTK2 but not LMTK2ala1325/1327 reduces Pro-Q Diamond
staining of KLC2. (b) Pro-Q Diamond (Pro-Q) phospho-staining
of KLC2 isolated from HeLa cells co-transfected with KLC2 and
either no siRNA, control siRNA (Ctrl siRNA), LMTK2 siRNA or
LMTK2 siRNA, followed by treatment with the PP1C inhibitor
tautomycetin (TMC). Transfected KLC2 was isolated by immu-
noprecipitation using the FLAG tag, and then analysed by Pro-Q
Diamond phospho-staining after SDS–PAGE. Also shown are
immunoblots of immunoprecipitated KLC2 (to demonstrate equal
amounts of KLC2 in the different samples) and LMTK2, which
was detected using anti-LMTK2 antibody. siRNA knockdown of
LMTK2 increases Pro-Q Diamond staining of KLC2 and this
effect is lost following treatment of the cells with tautomycetin.
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lated on C-terminal residues and translocates to the
nucleus to regulate the transcription of Smad2-respon-
sive genes (see for a review, Ross and Hill, 2008).
Correct transport of Smad2 by kinesin-1 is required for
Smad2 signalling (Batut et al., 2007). As LMTK2
regulates binding of Smad2 to KLC2, we therefore
enquired whether siRNA loss of LMTK2 influenced
TGFb-induced Smad2 phosphorylation, nuclear accu-
mulation and transcriptional activity. Treatment of
HeLa cells with TGFb increased endogenous Smad2
C-terminal phosphorylation without influencing total
Smad2 levels and this effect was inhibited by siRNA
knockdown of LMTK2 (Figure 5a). To investigate the
effect of LMTK2 on TGFb-induced Smad2 nuclear
accumulation, the subcellular distribution of Smad2 was
monitored by immunostaining. TGFb treatment in-
duced nuclear accumulation of endogenous Smad2 in
cells transfected with control siRNA, but this accumula-
tion was inhibited in LMTK2 siRNA knockdown cells
(Figure 5b). We also investigated how LMTK2 influ-
enced Smad2-mediated transcription. To do so, we
quantified transcriptional activity of a Smad2-respon-
sive luciferase reporter gene (2xARE-Luc) in response to
TGFb stimulation in HeLa cells. TGFb increased
2xARE-Luc activity in cells treated with control siRNA,
but this increase was significantly reduced in LMTK2
siRNA knockdown cells (Figure 5c).
Two gene targets for TGFb/Smad signalling are
the cdk inhibitors p15Ink4B and p21WAF1/Cip1
(Reynisdottir et al., 1995). The anti-oncogenic effect of
TGFb can thus be mediated, at least in part, by
increased expression of p15Ink4B and p21WAF1/Cip1,
which both inhibit cell proliferation (Lee and Yang,
2001). We therefore enquired whether siRNA loss of
LMTK2 influenced expression of p15Ink4B and
p21WAF1/Cip1. In agreement with previous studies
(Reynisdottir et al., 1995), TGFb increased the expres-
sion of both p15Ink4B and p21WAF1/Cip1, but
LMTK2 knockdown reduced this effect (Figure 5a).
Thus, siRNA knockdown of LMTK2 inhibits TGFb-
induced Smad2 phosphorylation and nuclear signalling,
including the expression of the cdk inhibitory proteins
p15Ink4B and p21WAF1/Cip1.
Discussion
Here, we show that LMTK2 regulates a pathway that
controls KLC2 phosphorylation and binding of Smad2
cargo. The pathway involves LMTK2 phosphorylation of
PP1Cthr320 to inhibit PP1C activity. Loss of PP1C activity
then induces inhibitory phosphorylation of GSK3bser9
and a reduction in KLC2 phosphorylation. This lowering
of KLC2 phosphorylation promotes binding of Smad2
(Figure 6). A similar pathway involving cdk5/p35
regulation of PP1C, GSK3b and KLC2 phosphorylation
has been described in neurons (Morfini et al., 2004). As
LMTK2 also binds to p35 (Kesavapany et al., 2003), it is
possible that LMTK2 may, at least in part, mediate this
neuronal cdk5/p35 effect on KLC2 phosphorylation
(Morfini et al., 2004). KLC2 is widely expressed and
kinesin-1 motors function in most if not all cell types, but
cdk5 is not active in many non-neuronal cells owing to the
absence of p35 (Lew et al., 1994; Tsai et al., 1994; Fu
et al., 2001). Signalling to control phosphorylation of
KLC2 by GSK3b cannot therefore involve cdk5/p35 in
many non-neuronal cells. It thus seems likely that
LMTK2 controls GSK3b phosphorylation of KLC2 in
these non-neuronal cell types.
One experimental approach we utilised was to
monitor PP1Cthr320 and GSK3bser9 phosphorylation
in cells in which LMTK2 expression was reduced using
siRNAs. Despite highly efficient knockdown of
LMTK2, phosphorylation of both PP1Cthr320 and
GSK3bser9 was lowered but not eliminated. These
observations suggest that there are other pathways that
control PP1Cthr320 phosphorylation and its regulation
of GSK3bser9. Indeed, PP1Cthr320 is also phosphory-
lated in non-neuronal cells such as that used here by
cdc2 and Nek2 (Dohadwala et al., 1994; Kwon et al.,
1997; Helps et al., 2000; Guo et al., 2002).
Phosphorylation of KLC2 by GSK3b negatively
regulates binding of cargoes and hence their transport
on kinesin-1 motors (Morfini et al., 2002). We show here
that LMTK2 impacts on this process to influence
binding of Smad2 to KLC2. Smad2 is a known KLC2
binding partner and kinesin-1 cargo (Batut et al., 2007).
Kinesin-1 is a major molecular motor that mediates
Figure 4 LMTK2 increases binding of Smad2 cargo to KLC2 in
HeLa cells. (a) Cells were co-transfected with KLC2 and Smad2,
and either control vector (Ctrl) or LMTK2. KLC2 was immuno-
precipitated with anti-FLAG antibody and the amounts of KLC2
and co-immunoprecipitating Smad2 then detected on immuno-
blots. Upper panels (IP) show the immunoprecipitations; lower
panels show the inputs in the two transfections. In the lower panel,
LMTK2 was detected using rabbit anti-LMTK2 antibody.
Transfection of LMTK2 increases the amount of Smad2 bound
to KLC2. (b) Cells were co-transfected with KLC2 and Smad2, and
either control siRNA (Ctrl), LMTK2 siRNA or LMTK2 siRNA,
followed by treatment with GSK3b inhibitor VIII as indicated
(GSK3In /þ ). KLC2 was immunoprecipitated with anti-FLAG
antibody and the amounts of KLC2 and co-immunoprecipitating
Smad2 then detected on immunoblots. Upper panels (IP) show the
immunoprecipitations; lower panels show the inputs in the two
transfections. In the lower panel, LMTK2 was detected using
rabbit anti-LMTK2 antibody. siRNA knockdown of LMTK2
decreases the amount of Smad2 bound to KLC2 and this effect is
rescued in cells treated with GSK3b inhibitor VIII.
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intracellular transport of numerous cargoes, including
intermediate filaments, mitochondria and a variety of
vesicle subtypes (Hirokawa et al., 2009). As there is
evidence that phosphorylation of KLC2 by GSK3b
affects binding of multiple cargoes (Morfini et al., 2002),
it seems likely that LMTK2 may likewise influence
binding of cargoes other than Smad2. LMTK2 may thus
affect a number of physiological processes requiring
kinesin-1-based motility.
Smad2 is required for the transduction of TGFb
signals. TGFb induces nuclear translocation of Smad2,
which in turn regulates the expression of TGFb-
responsive genes (see for reviews, Massague et al.,
2005; Massague and Gomis, 2006; Hill, 2009). Smad2 is
transported on kinesin-1 motors through the cytoplasm
and this transport is essential for Smad2 nuclear
signalling (Batut et al., 2007). We show that siRNA
loss of LMTK2 not only reduces binding of Smad2 to
KLC2, but also inhibits Smad2 nuclear signalling in
response to TGFb. Thus, loss of LMTK2 inhibits
TGFb-induced Smad2 phosphorylation, nuclear accu-
mulation and transcription of a Smad2 reporter gene.
Figure 5 siRNA knockdown of LMTK2 inhibits TGFb-induced Smad2 signalling in HeLa cells. (a) LMTK2 siRNA knockdown
inhibits TGFb-induced phosphorylation of Smad2 and expression of p15Ink4B and p21WAF1/Cip1. Cells were treated with either
vehicle () or TGFb (þ ) and the samples probed on immunoblots for phosphorylated (p-Smad2) and total Smad2, p15Ink4B (p15),
p21WAF1/Cip1 (p21) and for LMTK2. TGFb increases Smad2 phosphorylation and expression of p15Ink4B and p21WAF1/Cip1 in
control siRNA-transfected cells (Ctrl) and these effects are inhibited in LMTK2 siRNA-transfected cells. (b) LMTK2 knockdown
inhibits TGFb-induced nuclear accumulation of Smad2. Cells transfected with control (Ctrl) or LMTK2 siRNAs were treated with
vehicle or TGFb as indicated and immunostained for Smad2; nuclei were labelled with 40,6-diamidino-2-phenylindole. Bar chart shows
the relative nuclear/cytoplasmic (Nucleus/Cyto) signals in the different treated cells. Statistical significance was determined by one-way
analysis of variance, followed by least significant difference post hoc test. NX37; error bars are s.e.m. ***Po0.0001. Also shown is an
immunoblot from cells treated at the same time as for immunostaining to demonstrate efficient siRNA knockdown of LMTK2.
(c) LMTK2 knockdown inhibits TGFb-induced transcription of Smad2 reporter gene 2xARE-luc. Cells treated with control (Ctrl) or
LMTK2 siRNAs were transfected with 2xARE-Luc, FoxH1 and pRL-TK (Renilla luciferase) plasmids and treated with vehicle or
TGFb as indicated. 2xARE-Luc signals were normalised to pRL-TK transfection efficiency control signals. TGFb increases
transcription of 2xARE-Luc and this effect is inhibited in LMTK2 siRNA knockdown cells. Statistical significance was determined by
one-way analysis of variance, followed by least significant difference post hoc test. N¼ 24; error bars are s.e.m., ***Po0.0001. Also
shown is an immunoblot from cells treated at the same time as the assay to demonstrate efficient siRNA knockdown of LMTK2.
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We also show that LMTK2 loss inhibits expression of
the cdk inhibitors p15Ink4B and p21WAF1/Cip1 in
response to TGFb. Some of the anti-oncogenic effects of
TGFb are believed to be mediated by the expression of
these cdk inhibitory proteins (Reynisdottir et al., 1995;
Lee and Yang, 2001).
Loss of LMTK2 inhibited but did not abrogate
Smad2 nuclear signalling. As siRNA knockdown of
LMTK2 was highly efficient, it is possible that there are
other processes that may impact upon kinesin-1 trans-
port of Smad2. Indeed, there are two KLC isoforms
(KLC1 and KLC2) and only KLC2 is a target for
phosphorylation by GSK3b; LMTK2 regulation of
GSK3b activity will thus not influence any binding of
Smad2 to KLC1. Also, the C-terminal domains of
KLCs (which is where the GSK3b phosphorylation sites
in KLC2 are believed to be located; Morfini et al., 2002)
are altered by alternative splicing of mRNAs and this
also influences binding of cargoes (Wozniak and Allan,
2006). These other regulatory mechanisms may also
influence kinesin-1 transport of Smad2 and Smad2
signalling.
TGFb signalling functions in a variety of processes,
including cell division, differentiation, cell migration,
inflammation and apoptosis (Massague et al., 2005;
Massague and Gomis, 2006). Altered TGFb/Smad
signalling has also been associated with a number of
human diseases. These include some neurodegenerative
diseases such as Alzheimer’s disease and amyotrophic
lateral sclerosis (Town et al., 2008; Katsuno et al., 2011).
Interestingly, defective axonal transport of kinesin-1
cargoes is a prominent pathological feature of these
disorders (De Vos et al., 2008) and disruption to cdk5/
p35 (which phosphorylates LMTK2 to regulate its
activity) is also seen in Alzheimer’s disease and
amyotrophic lateral sclerosis (Bajaj et al., 1999; Kesa-
vapany et al., 2003; Su and Tsai, 2011). As such, altered
LMTK2 function may contribute to some neurodegen-
erative diseases.
In addition, TGFb/Smad signalling has been asso-
ciated with a variety of cancers (see for a review,
Massague, 2008). In normal and pre-malignant cells,
TGFb suppresses tumour formation, but in later stages
of tumourigenesis, TGFb signalling may be detrimental
and facilitate malignant progression (Massague, 2008).
The effects of the LMTK2 intron 9 genetic alteration
associated with prostate cancer on LMTK2 function are
not known. However, recent evidence indicates that
LMTK2 expression may be significantly reduced in
malignant prostate cancer tissues and that this may be
due to the intron 9 change (Harries et al., 2010). If this
proves to be the case, then LMTK2 stimulation of
Smad2 binding to KLC2 and transport on kinesin-1
may be inhibited in prostate cancer cells. In addition,
LMTK2 has recently been shown to associate with
myosin VI and to regulate its function in cellular
transport (Chibalina et al., 2007; Inoue et al., 2008).
Altered expression of myosin VI has also been seen in
prostate cancer (Su et al., 2001; Puri et al., 2010). Thus,
LMTK2 modulates the function of two different
molecular motors whose functions may impact on
prostate cancer.
Materials and methods
Antibodies
The following antibodies were used: anti-Myc-tag (9B11), anti-
phospho-PP1Ca (Thr320), anti-phospho-GSK3b (Ser9), anti-
phospho-SAPK/JNK, anti-SAPK/JNK, anti-Smad2 (86F7),
anti-phospho-Smad2 (Ser465/467) (138D4), anti-p15INK4B
(all from Cell Signaling Technology, Danvers, MA, USA);
anti-PP1Ca (E-9) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA); anti-GSK3b and anti-Smad2/3 (BD Biosciences,
Franklin Lakes, NJ, USA); anti-FLAG (M5) (Sigma, Poole,
UK); and anti-p21/WAF1/Cip1 (Abcam, Cambridge, UK).
The rabbit LMTK2 polyclonal antibody was as described
(Chibalina et al., 2007).
Plasmids
LMTK2 cDNA was generated from CD1 mouse brain by
reverse transcription–polymerase chain reaction using a
SuperScript III Platinum Reverse Transcription–Polymerase
Chain Reaction Kit (Invitrogen, Paisley, UK) using the
following primer set: 50-GACCGCGCGGTGGACGAGA
TG-30 and 50-GGAGTGGATTGCGTTGCTCAGGTG-30.
An myc tag was inserted onto the C terminus by polymerase
chain reaction and LMTK2-myc cloned into pCIneo (Prome-
ga, Southampton, UK). To generate the LMTK2ala1325/1327,
LMTK2 valine1325 and phenylalanine1327 were both mutated to
alanine using a QuikChange XL Site-Directed Mutagenesis
Kit (Stratagene, Amsterdam, The Netherlands) and the
following primer set: 50-GGAAGAAGGAAAAGAAGGCA
GCGACAGCTTTCGATGATGTCACCG-30 and 50-CGGT
GACATCATCGAAAGCTGTCGCTGCCTTCTTTTCCTTC
TTCC-30. Human PP1Ca in pCMV6-XL4 was from Origene
(Rockville, MD, USA). KLC2 cDNA was from Source
Bioscience (Nottingham, UK); an amino-terminal FLAG tag
was added by polymerase chain reaction and FLAG-KLC2
cloned into pCIneo. Plasmids for GFP-Smad2, GSK3b,
forkhead activin signal transducer FAST1 (FoxH1) and
2xARE-Luc were as described previously (Lovestone et al.,
Figure 6 Model showing the proposed mechanism for LMTK2
regulation of KLC2 phosphorylation and binding of Smad2.
LMTK2 directly phosphorylates PP1C on thr320 to reduce PP1C
activity (1). Reduced PP1C activity induces an increase in
inhibitory GSK3bser9 phosphorylation (2). This lowering of
GSK3b activity reduces KLC2 phosphorylation (3) to promote
binding of Smad2 cargo (4).
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1994; Zhou et al., 1998; Noda et al., 2006; Batut et al., 2007).
pRL-TK Renilla luciferase reporter control plasmid was from
Promega. For controls and so that all transfections received
the same amounts of DNA, pCIneo vector containing the
Escherichia coli chloramphenicol acetyltransferase was used as
described (Guidato et al., 1998).
Yeast two-hybrid screen
The yeast two-hybrid screen was performed using a pre-
transformed human brain cDNA library (Clontech, Mountain
View, CA, USA) with the cytoplasmic domain of LMTK2
(amino acids 67–1443) as the ‘bait’ cloned into pY1 (Chibalina
et al., 2007). Methods were according to the instructions
provided by Clontech. Following mating, yeast underwent
tryp-/leu-/his- selection and vigorously growing clones were
subjected to b-galactosidase assays. Prey plasmids were
rescued by transformation into E. coli and positive plasmids
identified by co-transformation back into yeast either alone or
with LMTK2 bait as described elsewhere (McLoughlin and
Miller, 1996).
Cell culture and transfection
HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum and 2mM L-
glutamine (Invitrogen). Cells were transfected using Exgen 500
(Fermentas, Burlington, ON, Canada) according to the
manufacturer’s instructions except for immunofluorescence
and reporter gene assays where Lipofectamine 2000 (Invitro-
gen) was used, again according to the manufacturer’s
instructions. Lipofectamine 2000 was used for immunostaining
since Exgen can give background staining with 40,6-diamidino-
2-phenylindole, which was used as a nuclear label (see
Immunofluorescence studies below). For siRNA knockdowns,
cells were transfected with Oligofectamine (Invitrogen) accord-
ing to the manufacturer’s instructions. Human LMTK2 was
targeted with four different siRNAs that were all obtained
from ThermoFisher (Lafayette, CO, USA): 2068 (50-UCAGG
AGCGUUGAACUUGA-30), 1158 (50-GCAGGUACAAGG
AGGAUUA-30), 1262 (50-GCAGAUCAGACUAAGUAU
A-30) and 1972 (50-GUAGUAACUUGGAGCUUGA-30).
Unless indicated, all four siRNAs were used in combination
and these gave knockdowns that were equivalent or greater
than the individual siRNAs; this is in agreement with previous
studies that also used these siRNAs (Chibalina et al., 2007).
Control siRNAs were also from ThermoFisher. Cells were
harvested for analyses 4 days after siRNA treatment. Where
described, cells were treated with 5mM tautomycetin (Merck
Chemical Ltd, Beeston, UK) or 1mM GSK3b inhibitor VIII
(AR-A014418; N-(4-nethoxybenzyl)-N0-(5-nitro-1,3-thiazol-2-
yl)urea) for 5 h before harvesting. TGFb (Sigma) was used at
1 ng/ml for the times indicated.
SDS–PAGE and immunoblotting
Cells were harvested for sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis (SDS–PAGE) by washing with
phosphate-buffered saline pre-warmed at 37 1C and scraping
into SDS–PAGE sample buffer and immediately heating to
100 1C. Samples were separated on 8 or 10% (w/v) acrylamide
gels, transferred to Protran nitrocellulose membranes
(Schleicher & Schuell, Dassel, Germany) using a Transblot
system (BioRad, Hercules, CA, USA) and following blocking,
probed with primary antibodies. Following washing, the blots
were incubated with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit immunoglobulins and developed
using an enhanced chemiluminescence system (GE Healthcare,
Piscataway, NJ, USA).
Immunoprecipitation and Pro-Q Diamond staining
Immunoprecipitation assays were performed essentially as
described (Vagnoni et al., 2011). Briefly, cells were lysed in ice-
cold immunoprecipitation (IP) buffer comprising 20mM HEPES
(pH 7.4), 100mM NaCl, 1% Triton X-100, 10% glycerol, 5mM
EDTA, 0.5mM sodium orthovanadate, 25mM sodium fluoride,
20mM b-glycerophosphate and protease inhibitors (Complete,
Roche, Burgess Hill, UK) for 30min. Following centrifugation
at 16 000 g for 30min at 4 1C, the supernatants were pre-cleared
with protein G-Sepharose beads (Sigma) for 1h at 4 1C, and then
incubated with primary antibodies for 16h at 4 1C. Antibodies
were captured with protein G-Sepharose beads and following
washing with immunoprecipitation buffer, bound proteins were
eluted by incubation in SDS–PAGE sample buffer and heating
at 100 1C. Samples were then analysed by immunoblotting and
Pro-Q Diamond staining. For Pro-Q Diamond staining, gels
were incubated with Pro-Q Diamond phosphoprotein gel stain
(Invitrogen) according to the manufacturer’s instructions and
signals captured using an Ettan DIGE Imager (GE Healthcare).
In vitro phosphorylation studies
Comparative in vitro phosphorylation studies of phosphor-
ylase b (Sigma) by LMTK2 and LMTK2ala1325/1327 were
performed essentially as described (Kesavapany et al., 2003).
Briefly, LMTK2 or LMTK2ala1325/1327 was isolated by im-
munoprecipitation from either LMTK2- or LMTK2ala1325/1327-
transfected cells using antibody 9B11 to the myc tag. LMTK2/
LMTK2ala1325/1327 were then incubated with 2mg of phosphor-
ylase b, 0.185MBq [g-32P]ATP in 25mM Tris–HCl (pH 7.5)
containing 10mM MgCl2, 5mM b-glycerophosphate, 0.1mM
sodium orthovanadate, 2mM dithiothreitol and 20 mM ATP for
20min at 30 1C in a final volume of 30ml. The reactions were
stopped by adding SDS–PAGE sample buffer and heating to
100 1C. Samples were separated by SDS–PAGE and the gels
stained with Coomassie blue (Sigma) and subjected to
autoradiography. For studies testing LMTK2 phosphorylation
of GSK3b, LMTK2 was again isolated by immunoprecipita-
tion from LMTK2-transfected cells using antibody 9B11 to the
myc tag. LMTK2 was then incubated with 1 mg of either
phosphorylase b or GSK3b (Cell Signaling Technology),
0.185MBq [g-32P]ATP in 25mM Tris–HCl (pH 7.5) containing
10mM MgCl2, 5mM b-glycerophosphate, 0.1mM sodium
orthovanadate, 2mM dithiothreitol, 20 mM ATP and 1 mM
GSK3b inhibitor VIII for 20min at 30 1C in a final volume
of 50ml. GSK3b inhibitor VIII was included to inhibit any
possible autophosphorylation of GSK3b, but was also added
to phosphorylase b reactions. The reactions were again
stopped by adding SDS–PAGE sample buffer and heating
to 100 1C, and equal volumes of the samples separated by
SDS–PAGE; the gels were then stained with Coomassie blue
and subjected to autoradiography.
Luciferase reporter assays
Luciferase assays were performed essentially as described by us
for other reporter gene assays (Lau et al., 2008) using a Dual-
Glo luciferase assay system according to the manufacturer’s
instructions (Promega). Briefly, HeLa cells transfected with
control or LMTK2 siRNAs were cultured for 3 days. They
were then transfected with reporter gene constructs and the
media replaced with Dulbecco’s modified Eagle’s medium
containing 0.2% foetal bovine serum with or without 1 ng/ml
TGFb, and the cells were cultured for a further 16 h as
described by others for similar assays (Noda et al., 2006;
Murakami et al., 2009). Cells were then harvested into Glo
lysis buffer (Promega) and the lysates transferred to a 96-well
luminometer plate (Wallac). An equal volume of Dual-Glo
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luciferase substrate was added and firefly luciferase activities
produced by the firefly luciferase reporter plasmid 2xARE-Luc
measured using a Wallac Trilux luminometer (Perkin Elmer,
Beaconsfield, UK). Renilla luciferase activities produced by the
co-transfected phRL-TK transfection efficiency control plas-
mid were then assayed by adding an equal volume of Dual-Glo
Stop&Glo substrate (Promega, Southampton, UK) (compris-
ing the stop solution for firefly luciferase and substrate for
Renilla luciferase) and re-measuring in the luminometer.
Firefly luciferase activities were normalised to the correspond-
ing Renilla luciferase activities and statistical analyses
performed using one-way analysis of variance with least
significant difference post hoc test.
Immunofluorescence studies
HeLa cells were transfected with control or LMTK2 siRNAs.
At 17 h before analyses, the media were replaced with
Dulbecco’s modified Eagle’s medium containing 0.2% foetal
bovine serum and the cells treated with 1 ng/ml TGFb (Sigma)
for 1 h. Cells were then fixed in 4% (w/v) paraformaldehyde in
phosphate-buffered saline for 20min, permeabilised with 0.5%
(w/v) Triton X-100 in phosphate-buffered saline for 10min,
blocked with 5% (v/v) foetal bovine serum in phosphate-
buffered saline for 1 h, and then probed with anti-Smad2 86F7
(Cell Signaling Technology) antibody diluted in blocking
solution. Following washing, the primary antibody was
detected using goat anti-rabbit immunoglobulin G coupled
to Alexa Fluor 568 (Molecular Probes) and the cells were
counterstained with 0.5mg/ml 40,6-diamidino-2-phenylindole
(Sigma) to visualise nuclei. Samples were mounted in
Vectashield (Vector labs) and imaged using a Leica
DM5000B microscope and  40/0.75 HCX FLUOTAR
objective (Leica Microsystems, Wetzlar, Germany). To moni-
tor the relative amounts of Smad2 in the cytoplasm and nuclei,
the mean Smad2 fluorescence signals were quantified in each
compartment using Image J (developed by Wayne Rasband,
NIH, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/); nuclei
were defined by 40,6-diamidino-2-phenylindole staining.
Analyses were performed from at least 37 cells from two
different experiments. Statistical significance was determined
using one-way analysis of variance with least significant
difference post hoc test.
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